Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
1997-08-26
2004-02-10
Prouty, Rebecca E. (Department: 1652)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C536S023500, C514S012200
Reexamination Certificate
active
06689864
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention.
The invention relates to the detection of genetic abnormalities that confer susceptibility to certain cancers in humans. More specifically, the invention relates to methods for detecting deletions of, or polymorphisms in, a newly discovered gene which encodes a tumor suppressor.
2. History of the Prior Art.
In recent years, a growing body of evidence has developed which supports the theory that the development of certain tumors is suppressed by gene products (“tumor suppressors”) which inhibit cellular proliferation (see e.g., the review in Marx, Science, 263:319-320, 1994). Conversely, if the tumor suppressors which would ordinarily be present in a cell are either absent (due, for example, to a gene deletion) or less active (due, for example, to a gene. mutation), tumor growth which would otherwise be inhibited may go unchecked. However, although the growth of certain tumors has been positively demonstrated to relate to the deletion of a tumor suppressor expressing gene, it has not yet been shown that mutations in the same genes will allow abnormal cellular proliferation to occur.
The growth cycle of eukaryotic cells is regulated by a family of protein kinases known as the cyclin-dependent kinases (“CDK's”). As shown in
FIG. 1
, the cyclins and their associated CDK's move cells through the three phases of the growth cycle (G
1
, S and G
2
, respectively) leading to division in the mitosis phase (M). The cyclin/CDK complexes whose role in cellular proliferation has been most clearly defined to date are the cyclin D/CDK enzymes, which are believed to assist in the progression of the G
1
growth cycle phase. Of these enzymes, cyclin D1 is believed to be an oncogene, whose overexpression stimulates excessive cell division through the continuous production of kinase, thus contributing to the development of cancers of, for example, the breast and esophagus. Cyclin D1 is specifically bound by CDK4 as part of a multiprotein complex that also consists of a protein known as p21 and cell nuclear antigen.
Known inhibitors of such cyclin/CDK overexpression include the tumor suppressor protein p53 and the protein product of the retinoblastoma (Rb) gene. Recently, another putative inhibitor (p16) was isolated and a cDNA for the inhibitor was partially sequenced by Serrano, et al,
Nature
, 366:704-710, 1993. The authors demonstrated that p16 binds CDK4 to inhibit the activity of the CDK4/cyclin D enzymes. Based on data indicating that p16 prevented phosphorylation by CDK/cyclin D of certain Rb growth cycle proteins, the authors proposed that p16 acts in vivo upstream and downstream of Rb to form a negative feedback loop to regulate cellular proliferation. However, no connection between p16 and the occurrence or inhibition of particular cancers was suggested, nor has any information been published concerning the genomic structure of the gene encoding
s p
16.
SUMMARY OF THE INVENTION
Prior to the publication of the Serrano, et al., article referred to above, the inventors discovered a tumor suppressor gene (hereafter, “CDK4I”) and identified its genomic structure (see, SEQ ID NO's: 1-2). In non-malignant cells, CDK4I maps to chromosome 9p21 and is physically adjacent to the gene for methylthioadenosine phosphorylase (MTAse) (see, FIG.
4
(
b
)). MTAse deficiencies resulting from deletions of, or mutations in, the gene for MTAse have been shown to be directly related to the onset of certain cancers (see, Nobori, et al,
Cancer Res
. 53:1098-1101, 1993, the disclosure of which are incorporated herein for reference regarding the role of MTAse in cancer development, and SEQ ID NO: 14, the nucleotide sequence of genomic MTAse).
Approximately one-half of all tumor cells which have been identified to date as either lacking CDK4I or containing mutations or rearrangements (collectively, “polymorphisms”) of the CDK4I gene also lack MTAse. The inventors have also identified mutations in the CDK4I gene which are present in the tumor cells of patients with certain cancers. The invention is therefore directed to methods to detect (a) deletions of the CDK4I gene in cells, and (b) polymorphisms, which deletions and polymorphisms are indicative of susceptibility to certain cancers.
More specifically, in one aspect, the invention comprises methods for detecting point mutations in, or deletions of, the CDK4I gene. Such methods include polymerase chain reaction (PCR) based assays, gel electrophoresis of single-strand conformation polymorphisms, direct sequencing, and restriction endonuclease digestion. Detection of a deletion of the CDK4I gene will preferably be performed by a unique competitive PCR technique.
In another aspect, the invention comprises methods for detection of CDK4I proteins and biologically active fragments thereof (collectively, “CDK4I”) in a biological cell sample.
In another aspect, the invention comprises screening protocols for susceptibility to particular cancers based on detection of polymorphisms associated with the occurrence of the cancers.
In another aspect, the invention comprises screening protocols for susceptibility to particular cancers based on detection of polymorphisms in, or deletions of, the genes for both CDK4I and MTAse, as well as detection of deficiencies in the products of the genes.
In another aspect, the invention comprises genomic CDK4I, expression products of the CDK4I gene, CDK4I and fragments thereof, as well as antibodies which will specifically bind CDK4I gene expression products, CDK4I and CDK4I fragments.
REFERENCES:
patent: 4681840 (1987-07-01), Stephenson et al.
patent: 5081230 (1992-01-01), Carney
patent: 5149628 (1992-09-01), Croce
patent: 5801236 (1998-09-01), Kamb
patent: 5843756 (1998-12-01), Stone et al.
patent: 5889169 (1999-03-01), Beach et al.
patent: 5962316 (1999-10-01), Beach et al.
patent: 5989815 (1999-11-01), Skolnick et al.
patent: 6037462 (2000-03-01), Kamb
patent: 6090578 (2000-07-01), Kamb
patent: WO 93/09945 (1993-05-01), None
Ewen et al., 74 Cell 1009-1020 (1993).*
Alberts et al., Molecular Biology of the Cell, Chapter 3, pp. 95-107 (1989).*
Kamb A. et al. A cell cycle regulator potentially involved in genesis of many tumor types, Science, 1994, 264, 436-440.*
Hussussian C. et al, Germline p16 mutations in familial melanoma, Nature Genetics, 1994, 8, 15-21.*
Serrano M. et al. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4, Nature, 1993, 366, 704-707.*
Kamb A. et al. A cell cycle regulator potentially involved in genesis of many tumor types, Science, 1994, 264, 436-440.*
Hussussian C. et al, Germline p16 mutations in familial melanoma, Nature Genetics, 1994, 8, 15-21.*
Nobori T. et al, Deletion of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers, Nature, 1994, 368, 753-756.*
ATCC Catalojue of Recombinant DNA Materials, Third Ed, 1993, Editors D.R. Moglott and WC Nierman, p. 9.*
Hayashi et al. Biochemical Biophys. Res. Comun. 202:1426-30, 1994.*
Xu et al, Cancer Research 54:5262-5264, 1994.*
Nobori et al. Cancer Research 53: 1098-1101, 1993.*
Dorland's Illustrated Medical Dictionary,27thEdition, W.B. Saunders Company, p. 461, (1988).
Freeman, et al., “Clinical Trials in Gene Therapy,”Advanced Drug Delivery Reviews,vol. 12, pp. 169-183, (1993).
Goldberg, et al., “Models of Neoplasia and Their Diagnostic Implications: A Historical Perspective,”Clinical Chemistry,vol. 39, No. 11(B), pp. 2360-2374, (1993).
Gutierrez, et al., “Gene Therapy for Cancer,”The Lancet,vol. 339, pp. 715-721, (Mar. 21, 1992).
Hebert, et al., “Candidate Tumor-Suppressor Genes MTS1 (p16INK4A) and MTS2(p15INK4B) Display Frequent Homozygous Deletions in Primary Cells From T-But Not From B-Cell Lineage Acute Lymphoblastic Leukemias,”Blood,vol. 84, No. 12, pp. 4038-4044, (Dec. 15, 1994).
James, “Towards Gene-Inhibition Therapy: A Review of Progress and Prospects in the Field of Antiviral Antisense Nucleic Acids and Ribozymes,”Antiviral Chemistry&Chemotherapy,vol. 2, No. 4, pp. 191-214, (1991).
Mori, et al., “Frequent Somatic Mutatio
Carson Dennis A.
Nobori Tsutomu
Prouty Rebecca E.
The Regents of the University of California
Townsend and Townsend / and Crew LLP
Walicka Malgorzata
LandOfFree
Cyclin dependent kinase 4 inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclin dependent kinase 4 inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclin dependent kinase 4 inhibitor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3338794